Collaboration Details

Print  Close

Title of Collaborative Activity:

NCI/FDA Memorandum of Understanding for Proteomics

Description of Collaborative Activity:

This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the NCI (Office of Cancer Clinical Proteomics Research) and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development.

Type of Collaborative Activity:

Research Initiative

Year the Collaborative Activity Originated:


NIH Participating Institutes/Centers/Office of the Director:


HHS Agency Collaborators on this Activity: